Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have revolutionized cancer treatment. However, fewer than 20% of patients respond to ...

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

Iovance stock drops 90% despite historic approval for Amtagvi. Click here for a full investment analysis of IOVA stock.